Patients with two copies of the CYP2A6*17 allele or one copy of the *17 allele in combination with one copy of the *1A, *4A, *20 or *35 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele while patients with two copies of the *17 allele or one copy of the *17 allele in combination with the *1A allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1A allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.